English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
日本語
By Ben Glickman
Illumina lowered its full-year revenue guidance, anticipating more cautious consumers.
The San Diego-based gene-sequencing company now expects a loss per share of $1.93 to $2.08, compared with prior guidance of a 3- to 28-cent loss. Analysts polled by FactSet expect per-share losses of $1.41.
Illumina also expects revenue to grow about 1% from the prior year, compared with earlier guidance of 7% to 10% growth.
Interim Chief Executive Charles Dadswell said the company was anticipating more cautious consumers and a drawn-out recovery in China, which would eat into results for the rest of this year.
Write to Ben Glickman at [email protected]
Read the full article here
